OncoMatch/Clinical Trials/NCT07356245
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Is NCT07356245 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ruxolitinib for t-cell lymphoma.
Treatment: Ruxolitinib — This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: ALK positive
Anaplastic lymphoma kinase (ALK)+ ... ALCL with low international prognostic index (IPI) score (<2) in first complete remission
Excluded: DUSP22 positive
Dual specificity 22 (DUSP22)+ ALCL with low international prognostic index (IPI) score (<2) in first complete remission
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: stem cell transplant — autologous or allogeneic
between day +35 and +120 from auto-SCT or allo-SCT
Cannot have received: systemic therapy
Exception: radiation allowed
any other systemic therapy post-SCT (radiation allowed)
Cannot have received: JAK inhibitor (ruxolitinib)
Exception: disease progression to Ruxolitinib previously
Disease progression to Ruxolitinib previously
Cannot have received: investigational drug
Exposure to other investigational drugs within 4 weeks before enrollment
Lab requirements
Blood counts
ANC > 1000/mm3 without G-CSF for at least 3 days, platelets > 50K/mm3 without transfusion for at least 3 days, hemoglobin (Hb) > 8.0 g/dL without transfusion for at least 3 days
Kidney function
CKD-EPI eGFR ≥ 30 ml/min
Liver function
total Bilirubin < 1.5 x ULN, alanine aminotransferase (ALT) ≤ 3 x ULN
Cardiac function
ejection fraction more than 45%, SpO2 > 92% without supplemental oxygen
Adequate hematologic function defined by absolute neutrophil count (ANC) > 1000/mm3 without granulocyte colony-stimulating factor (G-CSF) for at least 3 days, platelets > 50K/mm3 without transfusion for at least 3 days and hemoglobin (Hb) > 8.0 g/dL without transfusion for at least 3 days. Adequate organ function defined by total Bilirubin < 1.5 x ULN, alanine aminotransferase (ALT) ≤ 3 x ULN, CKD-EPI eGFR ≥ 30 ml/min, SpO2 > 92% without supplemental oxygen and ejection fraction more than 45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify